Lockheed Martin Corporation (LOM)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 525.00 |
|---|---|
| 52-week range | 377.00 – 613.00 |
| Return, 1 month / 3 months | +15.1% / +16.6% |
| Return, 1 year / 3 years | +28.9% / +33.7% |
| Trend | Uptrend |
| RSI (14) | 76 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -25.9% |
| Average daily value traded | 0.22M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lockheed Martin Corporation is an American aerospace and defence company based in Bethesda, Maryland. It designs and builds military aircraft, including fighter jets and transport planes, along with missiles, rockets, satellites and other defence systems. Its main customers are government defence and space agencies, chiefly in the United States, and it also supplies related support and services for those systems. The company works across aeronautics, missiles and fire control, rotary and mission systems, and space.
Lockheed Martin Corporation trades under the code LOM on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lockheed Martin Corporation (LOM) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 525.00 on 22 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 220 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 28.9% and over the last three months it rose 16.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 8.4% | ||
| From 52-week high | -9.5% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 16.6% | ||
| 6-month return | 12.0% | ||
| 12-month return, skipping the last month | 12.0% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.9% | ||
| Liquidity | 55 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.22M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 4 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +11.1% |
|---|---|
| 1 month | +15.1% |
| 3 months | +16.6% |
| 6 months | +12.0% |
| 1 year | +28.9% |
| 3 years | +33.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 469.64 / 484.22 |
|---|---|
| Golden / death cross (60 days) | Death, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12.16 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2026 | USD 3.0688 |
| 1 Jun 2026 | USD 3.0688 |
| 2 Mar 2026 | USD 3.0688 |
| 1 Dec 2025 | USD 3.0688 |
| 2 Sep 2025 | USD 2.9354 |
| 2 Jun 2025 | USD 2.9354 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.